Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Type
Public
HQ
Princeton, US
Founded
2002
Size (employees)
48 (est)
Advaxis was founded in 2002 and is headquartered in Princeton, US

Key People at Advaxis

Daniel J. O’Connor

Daniel J. O’Connor

President, Chief Executive Officer and Director
Thomas A. Moore

Thomas A. Moore

Chairman / CEO
Thomas J. McKearn

Thomas J. McKearn

Director
Roni A. Appel

Roni A. Appel

Director
Richard Berman

Richard Berman

Director
Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has office in Princeton
Princeton, US

Advaxis Metrics

Advaxis Summary

Market capitalization

$368 M

Closing share price

$8.93
Advaxis's current market capitalization is $368 M.

Advaxis Financials

Advaxis's revenue is $1 M in FY, 2014
FY, 2015FY, 2014FY, 2013

Revenue

$1 M$1.86 M

Revenue growth, %

-46.3%

Operating income

$-48.7 M$-19.5 M$-69.5 M

Operating expense total

$48.7 M$20.5 M$71.4 M

Net Income

$-47 M$-16.5 M$-67.5 M

Operating cash flow

$49 M$-2.95 M$20.6 M

Advaxis Market Value History

We estimate that Advaxis's current employees are approximately 27% female and 73% male.

Advaxis Online Presence

Advaxis Company Life

You may also be interested in